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Abstract
LmEGFRvIII vaccination is sufficient to protect against EGFRvIII-positive, 
but not heterogeneously EGFRvIII-expressing, tumor challenge 
Background
Results
Conclusions
Although the temporality of immune-related adverse events (irAE) 
during immunotherapy is well-recognized to be highly variable 
and often delayed,[1] post-immunotherapy irAE are rarely 
described and potentially under-recognized. In 2013, two cases 
were reported in abstract form in Deutschen Dermatologischen 
Gesellschaft.[2] Since then, the number of published reports has 
steadily increased, more than doubling since January 2018. With 
the increasing number of IO clinical trials in the curative 
neoadjuvant or adjuvant setting, larger numbers of patients will 
be exposed to IO in earlier stages of disease, often for limited 
courses. Given the potential for diagnostic misattribution in this 
setting, under-recognition of delayed immune-related events 
(DIRE) after completion of immunotherapy could pose a growing 
clinical hazard.
Methods
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Delayed Immune-Related Events After Discontinuation 
of Immunotherapy – DIRE Syndrome?
DIRE syndrome was defined as: newly diagnosed irAE ≥ 90 days 
post-immunotherapy discontinuation. We performed a literature 
review in PubMed between 1/1/2008 and 10/1/2018 (Figure 1) 
and included additional cases from our institution. Recrudescent 
irAE were excluded.
We identified 25 cases (Table 1), 22 by literature review (16 
melanoma, 5 NSCLC, 1 cutaneous SCC) and an additional 3 
cases treated neoadjuvantly at our institution (3 HNSCC). 
Seventy-seven percent of cases (17/22) identified by literature 
review were in the recurrent/metastatic context, while twenty-
three percent were adjuvant melanoma cases (5/22). Median 
interval from last immunotherapy dose to DIRE onset was 6 
months (range: 3 to 28 months). Median cumulative 
immunotherapy exposure was 4 doses (range: 1 to 36 doses).
An influx of neoadjuvant clinical trial design over the last 2-3 
years, incorporating brief IO exposure (typically checkpoint 
blockade) followed by surgical resection and/or adjuvant therapy 
in the curative setting, is attracting interest in multiple tumor 
types.[21-25] In this context, it will be necessary to recognize an 
emerging phenomenon, which we have termed DIRE syndrome 
(delayed immune-related events). Clinical vigilance has the 
potential to reduce morbidity, as these conditions are generally 
manageable with prompt diagnosis and initiation of treatment; or 
to avert unnecessary/harmful interventions due to misattribution 
(in the autoimmune meningitis case we report, an Ommaya 
reservoir was placed at an out-of-state hospital based on 
erroneous diagnosis of leptomeningeal carcinomatosis). Several 
confounding factors may contribute to misattribution following 
neoadjuvant IO: 1) subsequent standard of care treatments with 
potentially overlapping toxicity; 2) brief duration of IO exposure; 
3) protracted process of diagnosis-by-exclusion. DIRE syndrome 
should therefore figure prominently in the differential diagnosis of 
new onset illness with unclear etiology, irrespective of post-
immunotherapy interval.
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PubMed Search Strategy
(checkpoint OR costimula* OR co-stimula* OR nivolumab OR pembrolizumab OR avelumab OR atezolizumab OR PD-1 OR PD1 OR durvalumab OR PD-L1 OR PDL1 OR ipilimumab OR tremelimumab OR CTLA-4 OR CTLA4 OR OX40 OR 4-1BB OR GITR 
OR CD27 OR CD40 OR ICOS) AND (adverse event* OR adverse reaction OR toxicit* OR irAE OR neurological OR hypophysitis OR encephalopathy OR meningitis OR thyroid* OR adrenal OR pneumonitis OR colitis OR dermatologic OR cutaneous OR 
vitiligo OR myocarditis OR arthritis OR neuropathy OR myopathy OR sarcoidosis OR nephr*) AND (delay* OR late OR timing OR after OR following OR year* OR months OR weeks) NOT allerg* NOT pollut* NOT mice NOT mouse NOT murine NOT rat NOT 
rats NOT monkey* NOT pig NOT bovine NOT rabbit NOT fetal NOT neonatal NOT pregnan* NOT miscarriage NOT menopaus* NOT particle* NOT nanoparticle* NOT hydrocarbon NOT vitro[Title] NOT vivo[Title] NOT preclinical[Title] NOT GVHD[Title] ] NOT 
graft[Title] NOT host[Title] NOT transplan*[Title] NOT reject*[Title] NOT allogeneic[Title] NOT allograft[Title]
Table 1
Figure 1
